Cargando…
Cost per responder of TNF-α therapies in Germany
Tumor necrosis factor α (TNF-α) inhibitors ranked highest in German pharmaceutical expenditure in 2011. Their most important application is the treatment of rheumatoid arthritis (RA). Our objective is to analyze cost per responder of TNF-α inhibitors for RA from the German Statutory Health Insurance...
Autores principales: | Gissel, Christian, Repp, Holger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544564/ https://www.ncbi.nlm.nih.gov/pubmed/23877487 http://dx.doi.org/10.1007/s10067-013-2332-1 |
Ejemplares similares
-
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach
por: Gissel, Christian, et al.
Publicado: (2015) -
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016) -
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
por: Gissel, C., et al.
Publicado: (2017) -
Assessing Telemedicine Efficiency in Follow-up Care With Video Consultations for Patients in Orthopedic and Trauma Surgery in Germany: Randomized Controlled Trial
por: Muschol, Jennifer, et al.
Publicado: (2022) -
TNFα rs1800629 Polymorphism and Response to Anti-TNFα Treatment in Behçet Syndrome: Data from an Italian Cohort Study
por: Padula, Maria Carmela, et al.
Publicado: (2023)